Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects
with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in
Study MT-1186-A02 to at least a 12-point decrease in Revised ALS Functional Rating Score
(ALSFRS-R) or death, whichever happens first, over the course of the study or until oral
edaravone is commercially available in that country
Phase:
Phase 3
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Development America, Inc.